摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino-2,4-dioxo-5-(3,4,5-trimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile

中文名称
——
中文别名
——
英文名称
7-amino-2,4-dioxo-5-(3,4,5-trimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
英文别名
7-amino-2,4-dihydroxy-5-(3,4,5-trimethoxyphenyl)-5H-pyrano[2,3-d]pyrimidine-6-carbonitrile;7-amino-2,4-dioxo-5-(3,4,5-trimethoxyphenyl)-1,5-dihydropyrano[2,3-d]pyrimidine-6-carbonitrile
7-amino-2,4-dioxo-5-(3,4,5-trimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile化学式
CAS
——
化学式
C17H16N4O6
mdl
——
分子量
372.337
InChiKey
AVNHCOVQARPUCM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    145
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    巴比妥酸3,4,5-三甲氧基苯甲醛丙二腈water glass 作用下, 以 neat (no solvent) 为溶剂, 反应 0.5h, 以88%的产率得到7-amino-2,4-dioxo-5-(3,4,5-trimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    液态玻璃组成对吡喃并[2,3-d]嘧啶衍生物催化制备的影响
    摘要:
    本研究的主要目的是使用液态玻璃作为催化剂催化制备5-芳基-1,3,4,5-四氢2H-吡喃并[2,3-d]嘧啶-6-腈衍生物。所有反应均在水中回流条件下进行。作为进一步的目标,使用高速球磨 (HSBM) 技术研究了该过程。研究了液态玻璃成分和添加金属氧化物杂质的影响。最近,含有至少一个吡喃并[2,3-d]嘧啶核心部分的化合物因其作为药物和生物活性化合物的潜力而在合成有机化学中受到了相当大的关注。吡喃并[2,3-d]嘧啶作为抗肿瘤、抗高血压、抗菌和抗利什曼病药物在医学上引起了人们的兴趣。吡喃并[2,3-d]嘧啶已通过多种方法生产。可以获得对合成程序的完整审查和关于这些化合物的讨论。分子式为 Na2(SiO2)nO 的液态玻璃是一种硅酸钠水溶液,可通过 NaOH (25%) 与 SiO2 反应或通过将碳酸钠与二氧化硅熔化来制备。数十年来,液态玻璃一直被用作粘合剂和涂层剂。液态玻璃是一种无毒、耐热
    DOI:
    10.1080/00304948.2019.1600124
点击查看最新优质反应信息

文献信息

  • Convenient and fast synthesis of various chromene pharmaceuticals assisted by highly porous volcanic micro-powder with nanoscale diameter porosity
    作者:Ali Maleki、Kobra Valadi、Saideh Gharibi、Reza Taheri-Ledari
    DOI:10.1007/s11164-020-04195-8
    日期:2020.9
    characterized by various analytical methods and suitably used for facilitating the organic synthesis reactions. Briefly, high reaction yield (99%) has been obtained in short reaction times (4 min) in the synthesis reactions of chromene pharmaceutical derivatives, through applying this highly efficient organometallic catalyst. From mechanistic aspect, effective electronic interactions between heteroatoms
    在本文中,基于火山的中孔催化体系通过各种分析方法精确表征,并且适合用于促进有机合成反应。简而言之,通过使用这种高效的有机属催化剂,在色烯药物衍生物的合成反应中,在短的反应时间(4分钟)内获得了高的反应产率(99%)。从机械方面来看,杂原子如氧与浮石微粒表面之间的有效电子相互作用为共价结合提供了合适的条件。作为火山浮石的主要优点,可以提及通过酸处理激活化学官能团后的高催化性能,磁性和完全自然的基础(生物相容性和生物降解性)。高度多孔的结构导致反应物截留在微小的孔中并被活化以进行共价结合。此外,作为该催化剂的另外的优异之处,可以提到颗粒分离中的极大便利性和极大的可重复使用性。
  • Nio Nanoparticles: A Highly Efficient Catalyst for the One-Pot Three- Component Synthesis of Pyrano [2, 3-D] Pyrimidine Derivatives in Green Reaction Media
    作者:Ellahe Sabbaghnasab、Enayatollah Sheikhhosseini
    DOI:10.2174/1570178618666211001115655
    日期:2022.7
    Abstract:

    NiO nanoparticles are utilized to effectively strengthen annulated pyrano [2,3-d] pyrimidine synthesis through primary Knoevenagel, following Micheal and ultimate heterocyclization reactions of aldehyde, malononitrile, and barbituric acid. The characteristics of NiO nanoparticles are identified using advanced techniques, such as IR, UV, EDX, XRD, SEM, and TEM. The nano-NiO particles are mostly below < 100 nm in size with uniform spherical shapes. The adopted approach is advantages owing to its simple processing, relatively short reaction time, often good to high average yields, convenient workability, and environmental friendliness.

    摘要:使用NiO纳米颗粒有效地强化了环戊基喃[2,3-d]嘧啶的合成,通过首要的Knoevenagel,随后的Michael和最终的醛,马隆酸腈和巴比妥酸的杂环化反应。采用先进的技术,如IR,UV,EDX,XRD,SEM和TEM,确定了NiO纳米颗粒的特性。纳米NiO颗粒的大小大多数在<100纳米,呈均一的球形。采用的方法具有简单的处理、相对较短的反应时间、常常具有良好的到高收率、方便的可操作性和环境友好性的优点。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione